Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study

Beran, Jiřı́; Reynales, Humberto; Põder, Airi; Yu, Charles; Pitisuttithum, Punnee; Yuan, Lee Li; Vermeulen, Wim; Verhoeven, Carole; Leav, Brett; Zhang, Bin; Sawlwin, Daphne; Hamers-Heijnen, Esther; Edelman, Jonathan M.; Smolenov, Igor

doi:10.1016/s1473-3099(20)30694-0

Cited by 33 publications

(28 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For the 2021–22 season, Fluad (aIIV3) is no longer expected to be available. The quadrivalent formulation (Fluad Quadrivalent, aIIV4) met prespecified immunogenicity criteria relative to a noninfluenza control vaccine in a randomized trial; although the primary efficacy outcome was not met, the majority of influenza infections during the study were associated with a mismatched A(H3N2) virus ( 84 , 85 ). In a second randomized study examining immunogenicity of aIIV4 relative to aIIV3, aIIV4 met prespecified noninferiority criteria compared with aIIV3 for all four viruses.…”

Section: Recommendations For the Use Of Influenza Vaccines 2021–22mentioning

confidence: 99%

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season

Grohskopf¹,

Alyanak²,

Ferdinands³

et al. 2021

MMWR Recomm. Rep.

250

148

View full text Add to dashboard Cite

Section: Recommendations For the Use Of Influenza Vaccines 2021–22mentioning

confidence: 99%

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season

Grohskopf¹,

Alyanak²,

Ferdinands³

et al. 2021

MMWR Recomm. Rep.

250

148

View full text Add to dashboard Cite

“…influenza vaccine containing MF59 ® , an oil-in-water emulsion, elicited higher antibody response in older individuals compared to the standard influenza vaccine and, interestingly, a broader antibody response also directed toward heterologous vaccine strains (103,418,419). Although the mode of action is not completely understood, MF59 ® is believed to activate innate immune cells and favor the germinal center reaction (420,421).…”

Section: Improved Vaccinesmentioning

confidence: 99%

Aging and Options to Halt Declining Immunity to Virus Infections

et al. 2021

View full text Add to dashboard Cite

Immunosenescence is a process associated with aging that leads to dysregulation of cells of innate and adaptive immunity, which may become dysfunctional. Consequently, older adults show increased severity of viral and bacterial infections and impaired responses to vaccinations. A better understanding of the process of immunosenescence will aid the development of novel strategies to boost the immune system in older adults. In this review, we focus on major alterations of the immune system triggered by aging, and address the effect of chronic viral infections, effectiveness of vaccination of older adults and strategies to improve immune function in this vulnerable age group.

show abstract

“…The immunogenicity, efficacy, and safety of aQIV were evaluated by two studies, the V118_20 [ 49 ] and the V118_18 [ 50 ].…”

Section: Resultsmentioning

confidence: 99%

The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment

Calabrò

Boccalini

Panatto

et al. 2022

IJERPH

View full text Add to dashboard Cite

Background. The elderly, commonly defined as subjects aged ≥65 years, are among the at-risk subjects recommended for annual influenza vaccination in European countries. Currently, two new vaccines are available for this population: the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose quadrivalent influenza vaccine (hdQIV). Their multidimensional assessment might maximize the results in terms of achievable health benefits. Therefore, we carried out a Health Technology Assessment (HTA) of the aQIV by adopting a multidisciplinary policy-oriented approach to evaluate clinical, economic, organizational, and ethical implications for the Italian elderly. Methods. A HTA was conducted in 2020 to analyze influenza burden; characteristics, efficacy, and safety of aQIV and other available vaccines for the elderly; cost-effectiveness of aQIV; and related organizational and ethical implications. Comprehensive literature reviews/analyses were performed, and a transmission model was developed in order to address the above issues. Results. In Italy, the influenza burden on the elderly is high and from 77.7% to 96.1% of influenza-related deaths occur in the elderly. All available vaccines are effective and safe; however, aQIV, such as the adjuvanted trivalent influenza vaccine (aTIV), has proved more immunogenic and effective in the elderly. From the third payer’s perspective, but also from the societal one, the use of aQIV in comparison with egg-based standard QIV (eQIV) in the elderly population is cost-effective. The appropriateness of the use of available vaccines as well as citizens’ knowledge and attitudes remain a challenge for a successful vaccination campaign. Conclusions. The results of this project provide decision-makers with important evidence on the aQIV and support with scientific evidence on the appropriate use of vaccines in the elderly.

show abstract

Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study

Cited by 33 publications

References 23 publications

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season

Aging and Options to Halt Declining Immunity to Virus Infections

The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment

Contact Info

Product

Resources

About